Cargando…
In vitro combination therapy of pathologic angiogenesis using anti-vascular endothelial growth factor and anti-neuropilin-1 nanobodies
OBJECTIVE(S): Emergence of resistant tumor cells to the current therapeutics is the main hindrance in cancer treatment. Combination therapy, which mixes two or more drugs, is a way to overcome resistant problems of cancer cells to current treatments. Nanobodies are promising tools in cancer therapy...
Autores principales: | Mohseni, Nastaran, Roshan, Reyhaneh, Naderi, Shamsi, Behdani, Mahdi, Kazemi-Lomedasht, Fatemeh |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mashhad University of Medical Sciences
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585540/ https://www.ncbi.nlm.nih.gov/pubmed/33149867 http://dx.doi.org/10.22038/ijbms.2020.47782.11000 |
Ejemplares similares
-
Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function
por: Kazemi-Lomedasht, Fatemeh, et al.
Publicado: (2018) -
A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis
por: Karami, Elmira, et al.
Publicado: (2020) -
In vivo immunotherapy of lung cancer using cross-species reactive vascular endothelial growth factor nanobodies
por: Kazemi-Lomedasht, Fatemeh, et al.
Publicado: (2017) -
Development of camelid monoclonal nanobody against SLC39A6 zinc transporter protein
por: Ghaderi, Hajarossadat, et al.
Publicado: (2021) -
Designing and Development of a Tandem Bivalent Nanobody against VEGF(165)
por: Khodabakhsh, Farnaz, et al.
Publicado: (2021)